Last reviewed · How we verify
Lorcaserin Dose #1
At a glance
| Generic name | Lorcaserin Dose #1 |
|---|---|
| Sponsor | Eisai Inc. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Real-World Evidence on the Cardiovascular Safety of CONTRAVE® in the United States (U.S.)
- Real World Effectiveness of Combining an Employer-based Weight Management Program With Medication for Chronic Weight Management in Employees With Obesity (PHASE4)
- Lorcaserin in Treating Chemotherapy-Induced Peripheral Neuropathy in Patients With Stage I-IV Gastrointestinal or Breast Cancer (PHASE1)
- Drug Interaction and Self Administration Studies of Compounds for Cocaine Use Disorder (PHASE1)
- Gene-by-Stress Interactions in Intervention Studies Significance (PHASE1)
- Evaluating Muscle Weakness Improvement With Lorcaserin in ICU (PHASE1, PHASE2)
- Pharmacokinetic Properties of Lorcaserin in Subjects With Renal Impairment (PHASE1)
- Abuse Potential of Single Doses of Lorcaserin in Healthy Recreational Polydrug Users (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Lorcaserin Dose #1 CI brief — competitive landscape report
- Lorcaserin Dose #1 updates RSS · CI watch RSS
- Eisai Inc. portfolio CI